(UroToday.com) In this study by Benjamin Lowentritt, he evaluates the real-world effectiveness and treatment adherence of apalutamide in men with non-metastatic castration-resistant prostate cancer (cM0 CRPC / nmCRPC). Based on the SPARTAN trial, apalutamide was approved for use in conjunction with androgen deprivation therapy (ADT) for men with cM0 CRPC.